Limits...
The mutational landscape of hepatocellular carcinoma.

Lee JS - Clin Mol Hepatol (2015)

Bottom Line: Recent studies in which all coding exons in HCC were sequenced have shed new light on the genomic landscape of this malignant disease.This review provides an overview of previously known oncogenes and new oncogene candidates in HCC that were uncovered from recent exome or whole-genome sequencing studies.This knowledge provides direction for future personalized treatment approaches for patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ABSTRACT
The development of hepatocellular carcinoma (HCC) is a complex process, and HCC arises from the accumulation of multiple genetic alterations leading to changes in the genomic landscape. Current advances in genomic technologies have revolutionized the search for genetic alterations in cancer genomes. Recent studies in which all coding exons in HCC were sequenced have shed new light on the genomic landscape of this malignant disease. Catalogues of these somatic mutations and systematic analysis of catalogued mutations will lead us to uncover candidate HCC driver genes, although further functional validation is needed to determine whether these genes play a causal role in the development of HCC. This review provides an overview of previously known oncogenes and new oncogene candidates in HCC that were uncovered from recent exome or whole-genome sequencing studies. This knowledge provides direction for future personalized treatment approaches for patients with HCC.

No MeSH data available.


Related in: MedlinePlus

Genetic alterations of ARID1A, ARID2, and TP53 in hepatocellular carcinoma. Mutation data were obtained from The Cancer Genome Atlas project hepatocellular carcinoma samples (n=193), which are displayed as columns.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4612282&req=5

Figure 2: Genetic alterations of ARID1A, ARID2, and TP53 in hepatocellular carcinoma. Mutation data were obtained from The Cancer Genome Atlas project hepatocellular carcinoma samples (n=193), which are displayed as columns.

Mentions: Interestingly, recent studies showed that ARID1A mutations are negatively associated with mutations in TP53 in gastric cancer,6970 indicating that ARID1A and TP53 may work together in codependent manner to suppress tumor development. Analysis of HCC mutation data from The Cancer Genome Atlas project also showed that mutations in ARID1A/ARID2 and were negatively associated with mutations in TP53, further supporting the idea that these 2 genes interact (Fig. 2). However, it remains to be determined how ARID1A interacts with TP53 or whether ARID1A or ARID2 can modulate TP53 activity.


The mutational landscape of hepatocellular carcinoma.

Lee JS - Clin Mol Hepatol (2015)

Genetic alterations of ARID1A, ARID2, and TP53 in hepatocellular carcinoma. Mutation data were obtained from The Cancer Genome Atlas project hepatocellular carcinoma samples (n=193), which are displayed as columns.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4612282&req=5

Figure 2: Genetic alterations of ARID1A, ARID2, and TP53 in hepatocellular carcinoma. Mutation data were obtained from The Cancer Genome Atlas project hepatocellular carcinoma samples (n=193), which are displayed as columns.
Mentions: Interestingly, recent studies showed that ARID1A mutations are negatively associated with mutations in TP53 in gastric cancer,6970 indicating that ARID1A and TP53 may work together in codependent manner to suppress tumor development. Analysis of HCC mutation data from The Cancer Genome Atlas project also showed that mutations in ARID1A/ARID2 and were negatively associated with mutations in TP53, further supporting the idea that these 2 genes interact (Fig. 2). However, it remains to be determined how ARID1A interacts with TP53 or whether ARID1A or ARID2 can modulate TP53 activity.

Bottom Line: Recent studies in which all coding exons in HCC were sequenced have shed new light on the genomic landscape of this malignant disease.This review provides an overview of previously known oncogenes and new oncogene candidates in HCC that were uncovered from recent exome or whole-genome sequencing studies.This knowledge provides direction for future personalized treatment approaches for patients with HCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ABSTRACT
The development of hepatocellular carcinoma (HCC) is a complex process, and HCC arises from the accumulation of multiple genetic alterations leading to changes in the genomic landscape. Current advances in genomic technologies have revolutionized the search for genetic alterations in cancer genomes. Recent studies in which all coding exons in HCC were sequenced have shed new light on the genomic landscape of this malignant disease. Catalogues of these somatic mutations and systematic analysis of catalogued mutations will lead us to uncover candidate HCC driver genes, although further functional validation is needed to determine whether these genes play a causal role in the development of HCC. This review provides an overview of previously known oncogenes and new oncogene candidates in HCC that were uncovered from recent exome or whole-genome sequencing studies. This knowledge provides direction for future personalized treatment approaches for patients with HCC.

No MeSH data available.


Related in: MedlinePlus